May 13, 2026 —
Voyager Therapeutics presented new three-month GLP toxicology data for VY1706, its investigational tau-silencing AAV gene therapy for Alzheimer’s disease, at ASGCT 2026 in Boston. The late-breaking presentation showed that VY1706 was well tolerated in non-human primates following a single intravenous dose, with no adverse clinical pathology or histopathological findings observed up to the highest dose tested, 5E13 vg/kg. Voyager’s IND application process for VY1706 remains on track for the second quarter of 2026, with first-in-human dosing expected in the second half of 2026.
VY1706 is designed to deliver a vectorized MAPT siRNA broadly across the central nervous system using an engineered, BBB-penetrant AAV capsid. By reducing MAPT mRNA and tau protein, the program aims to address tau pathology, one of the central biological features associated with Alzheimer’s disease. According to Voyager, the therapy uses ALPL as its primary blood-brain barrier receptor, enabling CNS distribution after systemic intravenous administration.
In the three-month GLP toxicology study, VY1706 produced dose-dependent reductions in tau-related markers across key brain regions in non-human primates. Treatment resulted in 51–75% reductions in MAPT mRNA and 48–64% reductions in tau protein at 13 weeks following a single IV dose. These findings support Voyager’s view that a one-time systemic AAV gene therapy could potentially silence both intracellular and extracellular tau-related disease biology.
In addition to the VY1706 late-breaking data, Voyager presented seven other oral and poster presentations at ASGCT, highlighting continued progress across its TRACER™ capsid discovery platform, capsid engineering, immune evasion, and manufacturing development. One oral presentation described the directed evolution of muscular and neuromuscular AAV capsid variants in mice and non-human primates. The top muscle-targeted capsid achieved substantially higher expression than AAV9, including 100-fold increased skeletal muscle expression in mice and 25–30-fold increased skeletal muscle expression in non-human primates, while neuromuscular capsids showed broad transduction with reduced liver exposure relative to AAV9.
Voyager also presented additional work focused on Alzheimer’s disease targets, including a bi-functional AAV strategy designed to reduce endogenous ApoE4 and express ApoE2 at physiological levels. Other presentations addressed AAV capsid immune evasion, including engineered capsids designed to evade pre-existing neutralizing antibodies and AI-designed AAV mutants optimized for antibody evasion while maintaining favorable CNS-transduction and manufacturing properties.
The company also highlighted advances in developability and manufacturing, including transduction-based assay cell lines for engineered capsids, affinity chromatography optimization for BBB-penetrant AAV capsids, and improved transfection platforms for scalable rAAV production. Together, these data reinforce Voyager’s broader strategy: combining next-generation AAV capsids, systemic delivery, RNA-based gene silencing, and scalable manufacturing to expand the reach of gene therapy for neurological and neuromuscular diseases.
If VY1706 enters the clinic as planned, it could become one of the first gene therapy approaches designed to target tau in Alzheimer’s disease through a single intravenous administration. While clinical safety and efficacy remain to be established, the ASGCT data mark an important translational milestone for CNS-penetrant AAV gene therapy and tau-targeted genetic medicine.
